Trastuzumab: all 614 studies that test it

Page 2 of 7. Open to participants first (88), then studies with results posted, then the rest; newest registration first within each.

• A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male SubjectsCompletedNCT03776240Phase 1Results posted
• MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast CancerCompletedNCT03767335Phase 1Results posted
• GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain MetastasesTerminatedNCT03765983Phase 2Results posted
• Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast CancerCompletedNCT03755141Phase 2Results posted
• A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast CancerCompletedNCT03674112Phase 2Results posted
• Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast CancerCompletedNCT03556358Phase 3Results posted
• Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMDTerminatedNCT03501979Phase 2Results posted
• Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BCCompletedNCT03417544Phase 2Results posted
• S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by SurgeryCompletedNCT03365882Phase 2Results posted
• 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast CancerCompletedNCT03364348Phase 1Results posted
• MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.CompletedNCT03321981Phase 2Results posted
• Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast CancerCompletedNCT03112590Phase 1/2Results posted
• Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerTerminatedNCT03101748Phase 1/2Results posted
• Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast CancerCompletedNCT03084237Phase 3Results posted
• Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerCompletedNCT03043313Phase 2Results posted
• Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) CancerCompletedNCT02954536Phase 2Results posted
• Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast CancerTerminatedNCT02907918Phase 2Results posted
• Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast CancerActive, not recruitingNCT02827877Phase 2Results posted
• Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain MetastasisTerminatedNCT02774681Phase 2Results posted
• Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric CancerTerminatedNCT02726399Phase 2Results posted
• A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced CancerCompletedNCT02721641Phase 3Results posted
• An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.CompletedNCT02657343Phase 1/2Results posted
• Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After SurgeryCompletedNCT02654119Phase 2Results posted
• T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedNCT02562378Phase 1Results posted
• A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-RadiotherapyCompletedNCT02536339Phase 2Results posted
• Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast CancerCompletedNCT02445586Phase 4Results posted
• Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment RegimenCompletedNCT02419742Phase 4Results posted
• Fasting on Newly Diagnosed Breast CancerTerminatedNCT02379585Phase 1/2Results posted
• Neoadjuvant Hormonal Therapy Combined With ChemoimmunotherapyTerminatedNCT02345772Phase 1/2Results posted
• Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular CharacteristicsTerminatedNCT02297230Phase 1/2Results posted
• A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)CompletedNCT02291289Phase 2Results posted
• Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain MetastasesCompletedNCT02260531Phase 2Results posted
• Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based TherapyCompletedNCT02252887Phase 2Results posted
• Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast CancerActive, not recruitingNCT02226276Not applicableResults posted
• PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond ProgressionCompletedNCT02213289Phase 2Results posted
• A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)CompletedNCT02187744Phase 3Results posted
• Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast CancerCompletedNCT02162667Phase 3Results posted
• Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast CancerTerminatedNCT02154529Phase 1/2Results posted
• A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast CancerCompletedNCT02149524Phase 3Results posted
• Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast CancerCompletedNCT02139358Phase 1/2Results posted
• A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast CancerCompletedNCT02091960Phase 2Results posted
• My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsCompletedNCT02091141Phase 2Results posted
• Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male SubjectsCompletedNCT02075073Phase 1Results posted
• Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast CancerCompletedNCT02066532Phase 1/2Results posted
• A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedNCT02019277Phase 3Results posted
• A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast CancerCompletedNCT02015676Phase 1/2Results posted
• A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial CancerTerminatedNCT02013765Phase 2Results posted
• A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial CancerCompletedNCT02006667Phase 2Results posted
• A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease ProgressionTerminatedNCT02005484Phase 2Results posted
• A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast CancerCompletedNCT01998906Phase 3Results posted
• A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)CompletedNCT01989676Phase 3Results posted
• Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast CancerCompletedNCT01959490Phase 2Results posted
• A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerCompletedNCT01940497Phase 3Results posted
• Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast CancerActive, not recruitingNCT01937117Phase 2Results posted
• A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast CancerTerminatedNCT01928615Phase 2Results posted
• Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal CancerCompletedNCT01928290Phase 2Results posted
• A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)CompletedNCT01926886Phase 3Results posted
• Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast CancerTerminatedNCT01912963Phase 2Results posted
• Cardiac Safety Study in Patients With HER2 + Breast CancerCompletedNCT01904903Phase 2Results posted
• Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast CancerCompletedNCT01901146Phase 3Results posted
• Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast CancerTerminatedNCT01897441Not applicableResults posted
• Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast CancerTerminatedNCT01891357Phase 2Results posted
• Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast CancerCompletedNCT01875367Phase 3Results posted
• Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast CancerTerminatedNCT01873833Phase 2Results posted
• Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast CancerCompletedNCT01855828Phase 2Results posted
• T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)CompletedNCT01853748Phase 2Results posted
• Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast CancerCompletedNCT01827163Phase 2Results posted
• Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCaCompletedNCT01796197Phase 2Results posted
• Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor CellsTerminatedNCT01779050Phase 2Results posted
• A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer PatientsCompletedNCT01764022Phase 3Results posted
• Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast CancerCompletedNCT01750073Phase 2Results posted
• Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast CancerCompletedNCT01730833Phase 2Results posted
• Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast CancerCompletedNCT01688609Phase 2Results posted
• A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast CancerCompletedNCT01674062Phase 2Results posted
• Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.CompletedNCT01649271Phase 1Results posted
• A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast CancerCompletedNCT01572038Phase 3Results posted
• A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerCompletedNCT01566721Phase 3Results posted
• A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast CancerCompletedNCT01565083Phase 2Results posted
• A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric CancerCompletedNCT01461057Phase 2Results posted
• A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction CancerTerminatedNCT01450696Phase 3Results posted
• Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast CancerTerminatedNCT01388647Phase 1/2Results posted
• Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic DiseaseCompletedNCT01387295Phase 2Results posted
• Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous CancerCompletedNCT01367002Phase 2Results posted
• A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast CancerTerminatedNCT01363986Phase 2Results posted
• Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid MalignanciesCompletedNCT01351350Phase 1Results posted
• Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC PatientsCompletedNCT01306942Phase 1/2Results posted
• A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain MetastasesCompletedNCT01305941Phase 2Results posted
• A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin TreatmentCompletedNCT01301729Phase 4Results posted
• A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.TerminatedNCT01290718Phase 2Results posted
• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerCompletedNCT01275677Phase 3Results posted
• Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT01273610Phase 2Results posted
• A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric CancerTerminatedNCT01260194Phase 4Results posted
• MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor MalignanciesCompletedNCT01235897Phase 1Results posted
• Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast CancerTerminatedNCT01220128Phase 2Results posted
• Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal CancerCompletedNCT01196390Phase 3Results posted
• CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric CancerCompletedNCT01191697Phase 2Results posted
• Trastuzumab and Vinorelbine in Advanced Breast CancerTerminatedNCT01185509Phase 2Results posted
• A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast CancerCompletedNCT01160211Phase 3Results posted
• A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric CancerCompletedNCT01130337Phase 2Results posted
• A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)CompletedNCT01120184Phase 3Results posted

← Trastuzumab overview